

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

**SANGAMO BIOSCIENCES ANNOUNCES SECOND-QUARTER 2002
TELECONFERENCE**

Richmond, California – July 17, 2002 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its second-quarter financial results on Wednesday, July 24, 2002 after the market closes. The earnings release will be followed by a conference call at 2:00 p.m. PDT, which will be open to the public. During the conference call, the company will review the results and discuss other business matters.

The conference call dial-in numbers are 800-730-7991 for domestic callers and 706-634-7552 for international callers. For those unable to listen in at the designated time, a conference call replay will be available for 1 week following the conference call, from approximately 5:00 p.m. PDT on July 24, 2002 to 5:00 p.m. PDT on July 31, 2002. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291 respectively. The conference ID number for the replay is 4925870.

About Sangamo

Sangamo BioSciences, Inc., of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company's most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Other therapeutics development programs are focused on cancer and infectious diseases. Sangamo's proprietary technology enables the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery, clinical diagnostics, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP TFs. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbors created by those sections. Actual results may differ materially from these forward-looking statements. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release. Further, Sangamo assumes no obligation to update any guidance given on its upcoming conference call.

Contact: Elizabeth Wolffe
510-970-6000, x271

###